Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: With No New Offerings, Kadmon Steals The Spotlight

Executive Summary

Initial public offering activity has been slow as the summer kicks into high gear, but a filing with SEC by Kadmon has peculiarities that promise high drama the likes of which only Sam Waksal could offer.

Advertisement

Related Content

IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
IPO Update: Haircuts Needed To Price Biotech Offerings
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Waksal's Kadmon rapidly builds on hepatitis C franchise with Valeant deals
Waksal's Kadmon acquires Three Rivers

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel